Case Report: Enfortumab vedotin and pembrolizumab in androgen pathway modulation-naive prostate cancer with high-volume metastatic burden

In recent history, enfortumab vedotin (EV) in combination with pembrolizumab (EV-pembrolizumab) has emerged at the front line of treatment in urothelial carcinoma for its marked efficacy and tolerability measured against prior standard-of-care chemotherapies. Advanced prostate cancer remains a universally incurable disease. We present, for the first time in the literature, a case of marked objective and clinical response to EV-pembrolizumab in androgen pathway modulator-naive prostate cancer with high-volume metastatic burden, offering unique insight and consideration for a new therapeutic approach in a challenging and common advanced disease.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-16
DOI
https://doi.org/10.3389/fonc.2026.1937935
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Enfortumab vedotin and pembrolizumab in androgen pathway modulation-naive prostate cancer with high-volume metastatic burden

Joshua T. Kowalczyk, Christopher J. Hoimes
1 links
Frontiers in Oncology
Prostate Cancer Treatment and Research
article

Case Report: Enfortumab vedotin and pembrolizumab in androgen pathway modulation-naive prostate cancer with high-volume metastatic burden

Joshua T. Kowalczyk, Christopher J. Hoimes
article en

Abstract

In recent history, enfortumab vedotin (EV) in combination with pembrolizumab (EV-pembrolizumab) has emerged at the front line of treatment in urothelial carcinoma for its marked efficacy and tolerability measured against prior standard-of-care chemotherapies. Advanced prostate cancer remains a universally incurable disease. We present, for the first time in the literature, a case of marked objective and clinical response to EV-pembrolizumab in androgen pathway modulator-naive prostate cancer with high-volume metastatic burden, offering unique insight and consideration for a new therapeutic approach in a challenging and common advanced disease.

Frontiers in OncologyVol. 16
Duke University (US), Duke Medical Center (US)
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon